ClinicalTrials.gg
Not yet recruitingNCT07107204Updated Sep 17, 2025

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

A Phase 1/2 interventional study of BT02 in Relapsed or Refractory Hematologic Malignancies, Leukemia and Lymphoma, sponsored by Biotroy Therapeutics. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-09-17.

Primary conditionHematologic NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hematologic Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Hematologic Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Biotroy Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years .

Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

02

Conditions studied

  • Relapsed or Refractory Hematologic Malignancies
  • Leukemia
  • Lymphoma
  • Multiple Myeloma (MM)
03

In context

Hematologic Neoplasms Reclassified

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

This study's planned enrollment of 116 is above the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Biotroy Therapeutics is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Hematologic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation with signed by the participant or their legal guardian and being willing and able to comply with all trial procedures.
  2. Age:≥18 and \<70 years, any gender.
  3. Diagnosis:Confirmed hematologic (leukemia, lymphoma, or multiple myeloma) .
  4. Leukemia-Specific Requirement:Bone marrow blast count ≥5% (morphological) at screening.
  5. .
  6. Status.
  7. Adequate organ and hematologic function.
  8. An activity status score of 0-1.
  9. A of ≥ 3 months.
  10. Eligible participants of (both males and females) must agree to using effective throughout the study period.

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia (APL).
  2. Patients with hereditary syndromes such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome.
  3. Patients with isolated extramedullary leukemia and multiple myeloma.
  4. Patients with uncontrolled active central nervous system leukemia (CNSL).
  5. Patients who have received anticancer therapy prior to administration.
  6. A history of active disease requiring systemic therapy within the past 2 years.
  7. A history of cardiovascular disease, severe cardiac rhythm/conduction abnormalities ,severe pulmonary disease that may lead to severe episodes of dyspnea,head trauma, impaired consciousness, epilepsy, cerebral ischemia, or cerebral hemorrhagic disease.
  8. A severe acute or chronic infection when enrollment.
  9. Remaining the toxic reaction in previous anti-tumor therapy that has not recovered to ≤ Grade 1 .
  10. Unresolved > grade 1 irAE or the history of a grade ≥ 3 irAE in previous immunotherapy, or known to the formulation of the product.
  11. Patients undergoing acute (GVHD) or moderate-to-severe chronic GVHD or systemic GVHD therapy.
  12. A history of other type of .
  13. Received a within 28 days prior to the administration of the investigational product.
  14. Poor compliance.
  15. A history of alcohol/drugs abuse.
  16. Current pregnancy or breastfeeding.
  17. Other severe physical or mental illnesses or abnormal laboratory test results that the investigator deems unsuitable for participation in this study considering safety and compliance.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    dose escalation and expansion

    Drug: BT02

Interventions

  • DrugBT02

    BT02 monoclonal antibody injection with intravenous administration every 2 or 3 weeks

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Through the study completion, an average of 2.5 years

  2. Dose limited toxicity(DLT)

    Time frame: Through the dose escalation phase, an average of 10 months

  3. Maximum tolerable dose(MTD)

    Time frame: Through the dose escalation phase, an average of 10 months

  4. Recommended phase 2 dose(RP2D)

    Time frame: Through the study completion, an average of 2.5 years

Secondary outcomes

  1. Objective response rate (ORR) on tumor assessments

    Time frame: Through the study completion, an average of 2.5 years

  2. Progression-free survival (PFS) on tumor assessments

    Time frame: Through the study completion, an average of 2.5 years

  3. Overall survival (OS)

    Time frame: Through the study completion, an average of 2.5 years

  4. Duration of response (DoR) on tumor assessments

    Time frame: Through the study completion, an average of 2.5 years

  5. Disease control rate (DCR) on tumor assessments

    Time frame: Through the study completion, an average of 2.5years

  6. Mean and median Area under the curve (AUC) of BT02 following first dose and repeated administration at each dose level

    Time frame: Through the study completion, an average of 2.5 years

  7. Mean and median Maximum concentration (Cmax) of BT02 following first dose and repeated administration at each dose level

    Time frame: Through the study completion, an average of 2.5 years

  8. ADA and NAb incidence

    Time frame: Through the study completion, an average of 2.5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jan 2028, 27 months later.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 6, 2025
StartEst.
Oct 2025
Primary completionEst.
Jan 2028
CompletionEst.
Apr 2028
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07107204
Lead sponsor
Biotroy Therapeutics
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Oct 2025 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Sep 17, 2025

Study contacts

Clinical development director
Contact
clin.oper@biotroy.cn
+86-18602185973
Ying Wang, MD
principal investigator · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BT02

Start the discussion